+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Glioblastoma Multiforme Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896202
  • Report
  • January 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • MORE
Market Overview

A brain tumor occurs when abnormal cells form as well as grow within a brain. Factors such as the increasing burden of brain disorders, strong R&D initiatives from key players and rising geriatric population are boosting the growth of the glioblastoma multiforme treatment market. As per the estimates of Globocan 2018, the number of new cases of brain cancer across the world was 296,851 in 2018. This leads to increased care providers shifting to the mainstream treatment associated with the glioblastoma treatment. Hence, the growing focus toward the development of better treatment options invites more cancer chemotherapy based companies to generate innovative drugs as well as explore different geographic regions to grow the sales of chemotherapy and radiation therapy products thus fueling the growth of glioblastoma multiforme treatment market.

However, low approval rates for novel therapies, reimbursement issues, and stringent regulatory guidelines are expected to restrain the growth of the global market in the forecast period.

Scope of the Report

As per the scope of the report, Glioblastoma Multiforme (GBM), also known as glioblastoma, is the most common type of malignant brain tumor. Brain tumor arises from abnormal growth of cancerous cells in the brain. The brain tumor is one of the leading causes of death, globally.

Key Market Trends

Chemotherapy Segment is Expected to Dominate the Market

Based on treatment, the market is segmented into chemotherapy, radiation therapy, and others. The chemotherapy segment is expected to dominate the market. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing generic products for the treatment of neurological diseases like brain stroke; as well as glioblastoma in order to maintain their competitive advantage and penetrate new regional markets across the developed and emerging markets. In addition, the pipeline of glioblastoma multiforme is rich with the number of drugs that are expected to receive FDA approval steadily over the period. Also, an increase in funding for companies involved in the research related to glioblastoma is expected to boost the interest of venture partner companies, investors and new mergers as well as acquisition-related to this segment of the studied market.

North America leads the Glioblastoma Multiforme Treatment Market

North America leads the glioblastoma multiforme treatment market, owing to a rise in funding initiatives and awareness among patients, followed by Europe. According to the American Society of Clinical Oncology (ASCO), in 2019, it is expected that an estimated 23,820 adults (13,410 men and 10,410 women) in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary CNS tumors. However, Asia Pacific is expected to grow at a faster rate due to the increasing awareness regarding advanced treatment options, and the presence of emerging economies in this region.

Competitive Landscape

The leading players in the global glioblastoma multiforme treatment market are - Arbor Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Brain Disorders
4.2.2 Strong R&D Initiatives from Key Players
4.2.3 Increased Aging Population
4.3 Market Restraints
4.3.1 Reimbursement Issues and Stringent Regulatory Guidelines
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment
5.1.1 Chemotherapy Temozolomide Bevacizumab Carmustine
5.1.2 Radiation Therapy
5.1.3 Others
5.2 By End User
5.2.1 Hospitals/Clinics
5.2.2 Ambulatory Surgical Centers
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Arbor Pharmaceuticals, LLC
6.1.2 Bristol-Myers Squibb Company
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Merck & Co. Inc.
6.1.6 Sun Pharmaceutical Industries Ltd.
6.1.7 Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Arbor Pharmaceuticals, LLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown